Financial assistance programs

Your Celgene Patient Support® Specialist will help explore available financial assistance resources for your patients. Based on patients’ financial need and insurance status, they may be eligible for one of the following options:

ABRAXANE co-pay assistance programs

Assistance is just a phone call away

To get started, call us at 1-800-931-8691 Monday-Friday 8AM-7PM EST or send us an e-mail.

Enroll online now

Access here

Financial assistance programs

Your Celgene Patient Support® Specialist will help explore available financial assistance resources for your patients. Based on patients’ financial need and insurance status, they may be eligible for one of the following options:

Assistance is just a phone call away

To get started, call us at 1-800-931-8691 Monday-Friday 8AM-7PM EST or send us an e-mail.

Enroll online now

access-here
aPlease note the program does not cover administration fees

INDICATIONS

ABRAXANE is indicated for:

  • The treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated
  • The first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy
  • The first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine

INDICATIONS

ABRAXANE is indicated for:

  • The treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated
  • The first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy
  • The first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine